New Zealanders have one of the highest rates of Multiple Sclerosis (MS) in the world. It is a debilitating neurological disease with no cure. In Multiple Sclerosis the body’s own immune system attacks and destroys the protective myelin coating surrounding nerve cells causing a variety of symptoms such as fatigue, muscle weakness, and ultimately leads to paralysis. Our study will investigate the ability of a newly identified class of therapeutic drug to repair damaged myelin utilising two preclinical models of MS. This research has the potential to significantly improve the quality of life of 2.5 million MS sufferers.